7,397 reports of this reaction
2.1% of all LEVONORGESTREL reports
#11 most reported adverse reaction
UTERINE PERFORATION is the #11 most commonly reported adverse reaction for LEVONORGESTREL, manufactured by Bayer HealthCare Pharmaceuticals Inc.. There are 7,397 FDA adverse event reports linking LEVONORGESTREL to UTERINE PERFORATION. This represents approximately 2.1% of all 357,584 adverse event reports for this drug.
Patients taking LEVONORGESTREL who experience uterine perforation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
UTERINE PERFORATION is a less commonly reported adverse event for LEVONORGESTREL, but still significant enough to appear in the safety profile.
In addition to uterine perforation, the following adverse reactions have been reported for LEVONORGESTREL:
UTERINE PERFORATION has been reported as an adverse event in 7,397 FDA reports for LEVONORGESTREL. This does not prove causation, but indicates an association observed in post-market surveillance data.
UTERINE PERFORATION accounts for approximately 2.1% of all adverse event reports for LEVONORGESTREL, making it a notable side effect.
If you experience uterine perforation while taking LEVONORGESTREL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.